SH
SHIEF.US Shield Therapeutics plc
- Market cap
- USD 46.6M
- P/E
- -
- P/B
- 86.73x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is SHIEF.US undervalued?
Graham numberThe Graham number of Shield Therapeutics plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shield Therapeutics plc fundamental analysis
No fundamental analysis for Shield Therapeutics plc yet.
Shield Therapeutics plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shield Therapeutics plc
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru (ferric maltol), a non-salt based oral therapy for patients to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, United Kingdom.
Full company profileShield Therapeutics plc financial statements
Shield Therapeutics plc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 304K | 637K | 11.9M | 719K | 10.4M | 1.52M | 4.47M | 13.1M | 32.2M | 49.7M |
| Gross Profit | 204K | 482K | 11.6M | 234K | 9.03M | 539K | 2.00M | 4.03M | 14.9M | 23.0M |
| Operating Income | -12.5M | -21.0M | -5.17M | -9.04M | -2.15M | -20.0M | -25.7M | -31.3M | -22.9M | -10.1M |
| EBITDA | - | -18.5M | -2.78M | -6.44M | 819K | -17.4M | -37.3M | -30.3M | -21.3M | -8.61M |
| Net Income | -15.0M | -19.6M | -1.79M | -8.80M | -2.63M | -19.3M | -40.4M | -33.3M | -27.2M | -17.7M |
| EPS | - | -0.17 | -0.02 | -0.08 | -0.02 | -0.09 | -0.16 | -0.04 | -0.03 | -0.02 |
| Balance Sheet | ||||||||||
| Total Assets | 52.4M | 45.0M | 43.4M | 36.3M | 32.5M | 44.4M | 22.1M | 48.8M | 57.5M | 65.2M |
| Total Liabilities | 3.99M | 3.76M | 2.95M | 4.17M | 2.25M | 3.38M | 16.6M | 33.8M | 58.8M | 80.3M |
| Shareholders' Equity | 48.4M | 41.2M | 40.4M | 32.1M | 30.3M | 41.0M | 5.43M | 15.0M | -1.32M | -15.1M |
| Cash & Short-term Investments | 21.0M | 13.3M | 9.78M | 4.14M | 2.94M | 12.1M | 2.82M | 13.9M | 6.52M | 11.6M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -10.3M | -16.2M | 151K | -4.07M | -1.40M | -16.7M | -18.2M | -37.1M | -6.77M | -3.38M |
| Capital Expenditure | 8.00K | 3.41M | 372K | 372K | 372K | 372K | 53.0K | 2.95M | 2.42M | 300K |
| Free Cash Flow | - | -19.6M | -3.52M | -5.45M | -1.42M | -18.8M | -20.1M | -40.1M | -9.19M | -3.68M |
| Ratios | ||||||||||
| ROE | -31.0% | -47.5% | -4.4% | -27.4% | -8.7% | -47.1% | -745.2% | -221.5% | - | - |
| ROA | -28.7% | -43.6% | -4.1% | -24.2% | -8.1% | -43.5% | -183.2% | -68.2% | -47.3% | -27.1% |
| Net Profit Margin | -4,939.5% | -3,075.0% | -15.1% | -1,223.9% | -25.3% | -1,272.9% | -905.4% | -254.4% | -84.5% | -35.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Shield Therapeutics plc dividends
Shield Therapeutics plc has not paid dividends in the last 10 fiscal years.
Last stock split: 1029:1000 on Dec 28, 2022.
Who owns Shield Therapeutics plc
- Insiders 61.51%
- Institutions 3.28%
- Public & others 35.22%
- Shares outstanding 1.07B
- Free float 414M
Shield Therapeutics plc company profile
- Company name
- Shield Therapeutics plc
- Ticker
- SHIEF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 61
- Fiscal year end
- December
- Address
- Northern Design Centre, Gateshead, United Kingdom, NE8 3DF
- Phone
- 44 1915 118 500
- Website
- shieldtherapeutics.com
About Shield Therapeutics plc
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru (ferric maltol), a non-salt based oral therapy for patients to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, United Kingdom.
Shield Therapeutics plc management
8- Mr. Karl Anders LundstromCEO & Director · born 1962
- Dr. Christian Karl Kurt Schweiger M.D., Ph.D.Co-Founder & Non Executive Director · born 1966
- Mr. Michael JensenChief Financial Officer
- Ms. Lucy Kate Huntington-BaileyGeneral Counsel, Chief Compliance Officer & Company Secretary
- Mr. David ChildsSenior VP of Manufacturing & Strategic Alliances
- Ms. Carol AkinolaHead of Pharmacovigilance & Medical Information
- Mr. Andrew HurleyChief Commercial Officer · born 1969
- Mr. Bryon KallertSenior Director of Financial Planning & Analysis